Brii Biosciences Limited announced topline cohort level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179 (VBI-2601), a first-in-class, Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha ("PEG-IFNa") in chronic hepatitis B ("CHB") patients compared with PEG-IFNa only treatment. The Company reported in previous studies that BRII-179 induced broad antibody and T-cell responses against Pre-S1, Pre-S2 and S epitopes in CHB patients. The cohort level unblinded data from the study demonstrated that in the intent to treat analysis at Week 24 (the end of treatment (the "EoT")), 26.3% (15 patients) treated with BRII-179/PEG-IFNa achieved hepatitis B surface antigen ("HBsAg") loss compared to 19.3% (11 patients) with placebo/PEG-IFNa a; at Week 36 (12 weeks follow-up), 24.6% (14 patients) treated with BRII -179/PEG-IF Na had HBsAg loss, compared to 14.0% (8 patients) with placebo/PEG-IFNa.

In the per protocol analysis at Week 24, 32.6% (15 patients) treated With BRII-179/Peg-IFNa achieved HBsAg loss compared to 21.6% (11 patients) with randomized, placebo-controlled and triple-blinded Phase 2 study. The Company believes that BRII-179 has the unique ability to distinguish patients who have significant intrinsic humoral immunity versus those who do not. In July 2023, the Company expanded the BRII-179 license from VBI Vaccines Inc. to global rights.

The Company is planning for additional combination studies in the near future to investigate BRII-179 as a primer to enhance antibody responses and enrich patients for potentially curative treatments. More detailed data will be shared at a future scientific conference. There is no assurance that BRII-179 or BRII-179 or BR II-179 or BRII-IFNa only treatment.

There is no assurance thatBRII-179 or BRII -179 or BRII-179. The Company is planning for further combination studies in the near future. There is no assurance that BrII-179 or BRII the Company is currently being conducted in the Phase 2 study.

The Company is planning for new combination studies in the near future, and the Company is planning for additional combination study. The Company is planning to investigate BRII-179 As a primer to enhance antibody responses, enrich patients for potentially curative treatment. More detailed data will be sharing at a future scientific conference.